Last 12 months
Inside the activity.
2 purchase rows · 116 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 15 |
| Dec 2025 | 0 | 2 |
| Jan 2026 | 0 | 29 |
| Feb 2026 | 0 | 7 |
| Mar 2026 | 0 | 31 |
| Apr 2026 | 0 | 9 |
| May 2026 | 0 | 6 |
| Jun 2026 | 0 | 11 |
| Jul 2026 | 2 | 6 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 16, 2026 Filed Apr 17, 2026 23:19 UTC |
Jenne KyleEVP, Chf GL Pdt Str Ofcr
|
SaleCommon Stock | 4,902 | $75.17 | $368,488.24 |
DisclosureSEC source: 0000874015-26-000171 · edgardoc.xml · nonDerivative · entry 2 Jenne Kyle · CIK 0001791857 · EVP, Chf GL Pdt Str Ofcr 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,713 F2 · kind: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice. F2 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.06 to $75.26 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4. Read SEC document |
| April 16, 2026 Filed Apr 17, 2026 23:19 UTC |
Birchler BrianEVP, Corp and Development Ops
|
SaleCommon Stock | 973 | $75.04 | $73,015.87 |
DisclosureSEC source: 0000874015-26-000170 · edgardoc.xml · nonDerivative · entry 2 Birchler Brian · CIK 0001970151 · EVP, Corp and Development Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,500 F2 · kind: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice. F2 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.01 to $75.06 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4. Read SEC document |
| April 16, 2026 Filed Apr 17, 2026 23:19 UTC |
Baroldi JosephEVP, Chief Business Officer
|
SaleCommon Stock | 5,619 | $74.56 | $418,952.64 |
DisclosureSEC source: 0000874015-26-000169 · edgardoc.xml · nonDerivative · entry 2 Baroldi Joseph · CIK 0001813775 · EVP, Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,535 F2 · kind: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice. F2 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.12 to $75.01 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4. Read SEC document |
| April 15, 2026 Filed Apr 17, 2026 23:19 UTC |
Jenne KyleEVP, Chf GL Pdt Str Ofcr
|
Exercise / conversionRestricted Stock Unit · Derivative | 12,226 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000874015-26-000171 · edgardoc.xml · derivative · entry 3 Jenne Kyle · CIK 0001791857 · EVP, Chf GL Pdt Str Ofcr 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,402 Underlying: Common Stock · 12,226 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F5 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F5 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| April 15, 2026 Filed Apr 17, 2026 23:19 UTC |
Jenne KyleEVP, Chf GL Pdt Str Ofcr
|
Exercise / conversionCommon Stock | 12,226 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-26-000171 · edgardoc.xml · nonDerivative · entry 1 Jenne Kyle · CIK 0001791857 · EVP, Chf GL Pdt Str Ofcr 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,615 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award. F1 · shares: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award. Read SEC document |
| April 15, 2026 Filed Apr 17, 2026 23:19 UTC |
PARSHALL B LYNNEDirector
|
SaleCommon Stock | 534 | $76.97 | $41,101.98 |
DisclosureSEC source: 0000874015-26-000172 · edgardoc.xml · nonDerivative · entry 2 PARSHALL B LYNNE · CIK 0001073385 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,344 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 6, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.85 to $77.115 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4. Read SEC document |
| April 15, 2026 Filed Apr 17, 2026 23:19 UTC |
PARSHALL B LYNNEDirector
|
SaleCommon Stock | 4,466 | $76.19 | $340,264.54 |
DisclosureSEC source: 0000874015-26-000172 · edgardoc.xml · nonDerivative · entry 1 PARSHALL B LYNNE · CIK 0001073385 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,878 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 6, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.77 to $76.70 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| April 15, 2026 Filed Apr 17, 2026 23:19 UTC |
Birchler BrianEVP, Corp and Development Ops
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,875 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000874015-26-000170 · edgardoc.xml · derivative · entry 3 Birchler Brian · CIK 0001970151 · EVP, Corp and Development Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,926 Underlying: Common Stock · 1,875 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F5 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F5 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| April 15, 2026 Filed Apr 17, 2026 23:19 UTC |
Birchler BrianEVP, Corp and Development Ops
|
Exercise / conversionCommon Stock | 1,875 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-26-000170 · edgardoc.xml · nonDerivative · entry 1 Birchler Brian · CIK 0001970151 · EVP, Corp and Development Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,473 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award. F1 · shares: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award. Read SEC document |
| April 15, 2026 Filed Apr 17, 2026 23:19 UTC |
Baroldi JosephEVP, Chief Business Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 10,837 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000874015-26-000169 · edgardoc.xml · derivative · entry 4 Baroldi Joseph · CIK 0001813775 · EVP, Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,312 Underlying: Common Stock · 10,837 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F5 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F5 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| April 15, 2026 Filed Apr 17, 2026 23:19 UTC |
Baroldi JosephEVP, Chief Business Officer
|
Exercise / conversionCommon Stock | 10,837 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-26-000169 · edgardoc.xml · nonDerivative · entry 1 Baroldi Joseph · CIK 0001813775 · EVP, Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,154 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award. F1 · shares: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award. Read SEC document |
| April 02, 2026 Filed Apr 2, 2026 23:43 UTC |
Devers Shannon L.EVP, Chief Human Resources Ofc
|
SaleCommon Stock | 6,193 | $74.05 | $458,613.33 |
DisclosureSEC source: 0000874015-26-000160 · edgardoc.xml · nonDerivative · entry 1 Devers Shannon L. · CIK 0002037721 · EVP, Chief Human Resources Ofc 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,348 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 24, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.62 to $74.2450 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| April 01, 2026 Filed Apr 2, 2026 23:43 UTC |
KLEIN JOSEPH IIIDirector
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 10,321 | $0.00 Strike: $41.08 | $0.00 |
DisclosureSEC source: 0000874015-26-000161 · edgardoc.xml · derivative · entry 7 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,321 shares Expires 2033-07-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2026 Filed Apr 2, 2026 23:43 UTC |
KLEIN JOSEPH IIIDirector
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $38.06 | $0.00 |
DisclosureSEC source: 0000874015-26-000161 · edgardoc.xml · derivative · entry 6 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2032-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2026 Filed Apr 2, 2026 23:43 UTC |
KLEIN JOSEPH IIIDirector
|
SaleCommon Stock | 2,216 | $75.95 | $168,314.06 |
DisclosureSEC source: 0000874015-26-000161 · edgardoc.xml · nonDerivative · entry 4 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,014 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 26, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.88 to $76.17 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4. Read SEC document |
| April 01, 2026 Filed Apr 2, 2026 23:43 UTC |
KLEIN JOSEPH IIIDirector
|
SaleCommon Stock | 20,105 | $75.50 | $1,517,987.82 |
DisclosureSEC source: 0000874015-26-000161 · edgardoc.xml · nonDerivative · entry 3 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,230 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 26, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.865 to $75.85 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| April 01, 2026 Filed Apr 2, 2026 23:43 UTC |
KLEIN JOSEPH IIIDirector
|
Exercise / conversionCommon Stock | 10,321 | $41.08 | $423,986.68 |
DisclosureSEC source: 0000874015-26-000161 · edgardoc.xml · nonDerivative · entry 2 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,335 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2026 Filed Apr 2, 2026 23:43 UTC |
KLEIN JOSEPH IIIDirector
|
Exercise / conversionCommon Stock | 12,000 | $38.06 | $456,720.00 |
DisclosureSEC source: 0000874015-26-000161 · edgardoc.xml · nonDerivative · entry 1 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,014 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 19, 2026 Filed Mar 23, 2026 23:36 UTC |
Schneider EugeneEVP, Chf Clinical Develop Ofcr
|
SaleCommon Stock | 5,812 | $70.97 | $412,486.36 |
DisclosureSEC source: 0000874015-26-000152 · primary_doc.xml · nonDerivative · entry 1 Schneider Eugene · CIK 0001838539 · EVP, Chf Clinical Develop Ofcr 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 63,890 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 19, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.76 to $71.375 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission,upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| March 17, 2026 Filed Mar 18, 2026 21:19 UTC |
HOUGEN ELIZABETH LEVP, Finance & CFO
|
SaleCommon Stock | 10,172 | $73.21 | $744,661.60 |
DisclosureSEC source: 0000874015-26-000146 · edgardoc.xml · nonDerivative · entry 7 HOUGEN ELIZABETH L · CIK 0001074773 · EVP, Finance & CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 82,660 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on December 9, 2025. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.11 to $73.28 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) on this Form 4. Read SEC document |
| March 16, 2026 Filed Mar 18, 2026 21:19 UTC |
HOUGEN ELIZABETH LEVP, Finance & CFO
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 60,299 | $0.00 Strike: $60.89 | $0.00 |
DisclosureSEC source: 0000874015-26-000146 · edgardoc.xml · derivative · entry 11 HOUGEN ELIZABETH L · CIK 0001074773 · EVP, Finance & CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 60,299 shares Expires 2027-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 16, 2026 Filed Mar 18, 2026 21:19 UTC |
HOUGEN ELIZABETH LEVP, Finance & CFO
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 61,041 | $0.00 Strike: $56.78 | $0.00 |
DisclosureSEC source: 0000874015-26-000146 · edgardoc.xml · derivative · entry 10 HOUGEN ELIZABETH L · CIK 0001074773 · EVP, Finance & CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 61,041 shares Expires 2028-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 16, 2026 Filed Mar 18, 2026 21:19 UTC |
HOUGEN ELIZABETH LEVP, Finance & CFO
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 20,541 | $0.00 Strike: $37.58 | $0.00 |
DisclosureSEC source: 0000874015-26-000146 · edgardoc.xml · derivative · entry 9 HOUGEN ELIZABETH L · CIK 0001074773 · EVP, Finance & CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,405 Underlying: Common Stock · 20,541 shares Expires 2033-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 16, 2026 Filed Mar 18, 2026 21:19 UTC |
HOUGEN ELIZABETH LEVP, Finance & CFO
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 33,118 | $0.00 Strike: $32.60 | $0.00 |
DisclosureSEC source: 0000874015-26-000146 · edgardoc.xml · derivative · entry 8 HOUGEN ELIZABETH L · CIK 0001074773 · EVP, Finance & CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 33,118 shares Expires 2032-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 16, 2026 Filed Mar 18, 2026 21:19 UTC |
HOUGEN ELIZABETH LEVP, Finance & CFO
|
SaleCommon Stock | 9,440 | $72.77 | $686,901.60 |
DisclosureSEC source: 0000874015-26-000146 · edgardoc.xml · nonDerivative · entry 6 HOUGEN ELIZABETH L · CIK 0001074773 · EVP, Finance & CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 92,832 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on December 9, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.71 to $72.88 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4. Read SEC document |
| March 16, 2026 Filed Mar 18, 2026 21:19 UTC |
HOUGEN ELIZABETH LEVP, Finance & CFO
|
SaleCommon Stock | 205,608 | $72.38 | $14,882,112.65 |
DisclosureSEC source: 0000874015-26-000146 · edgardoc.xml · nonDerivative · entry 5 HOUGEN ELIZABETH L · CIK 0001074773 · EVP, Finance & CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 102,272 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on December 9, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.70 to $72.70 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| March 16, 2026 Filed Mar 18, 2026 21:19 UTC |
HOUGEN ELIZABETH LEVP, Finance & CFO
|
Exercise / conversionCommon Stock | 20,541 | $37.58 | $771,930.78 |
DisclosureSEC source: 0000874015-26-000146 · edgardoc.xml · nonDerivative · entry 4 HOUGEN ELIZABETH L · CIK 0001074773 · EVP, Finance & CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 307,880 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 16, 2026 Filed Mar 18, 2026 21:19 UTC |
HOUGEN ELIZABETH LEVP, Finance & CFO
|
Exercise / conversionCommon Stock | 33,118 | $32.60 | $1,079,646.80 |
DisclosureSEC source: 0000874015-26-000146 · edgardoc.xml · nonDerivative · entry 3 HOUGEN ELIZABETH L · CIK 0001074773 · EVP, Finance & CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 287,339 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 16, 2026 Filed Mar 18, 2026 21:19 UTC |
HOUGEN ELIZABETH LEVP, Finance & CFO
|
Exercise / conversionCommon Stock | 61,041 | $56.78 | $3,465,907.98 |
DisclosureSEC source: 0000874015-26-000146 · edgardoc.xml · nonDerivative · entry 2 HOUGEN ELIZABETH L · CIK 0001074773 · EVP, Finance & CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 254,221 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 16, 2026 Filed Mar 18, 2026 21:19 UTC |
HOUGEN ELIZABETH LEVP, Finance & CFO
|
Exercise / conversionCommon Stock | 60,299 | $60.89 | $3,671,606.11 |
DisclosureSEC source: 0000874015-26-000146 · edgardoc.xml · nonDerivative · entry 1 HOUGEN ELIZABETH L · CIK 0001074773 · EVP, Finance & CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 193,180 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 10, 2026 Filed Mar 11, 2026 20:19 UTC |
Monia Brett PDirector · Chief Executive Officer
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 34,103 | $0.00 Strike: $60.89 | $0.00 |
DisclosureSEC source: 0000874015-26-000143 · edgardoc.xml · derivative · entry 11 Monia Brett P · CIK 0001537529 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 34,103 shares Expires 2027-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 10, 2026 Filed Mar 11, 2026 20:19 UTC |
Monia Brett PDirector · Chief Executive Officer
|
SaleCommon Stock | 17,591 | $76.34 | $1,342,909.25 |
DisclosureSEC source: 0000874015-26-000143 · edgardoc.xml · nonDerivative · entry 8 Monia Brett P · CIK 0001537529 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 242,662 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on December 8, 2025 F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.02 to $76.70 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (6) on this Form 4. Read SEC document |
| March 10, 2026 Filed Mar 11, 2026 20:19 UTC |
Monia Brett PDirector · Chief Executive Officer
|
SaleCommon Stock | 16,512 | $75.47 | $1,246,234.94 |
DisclosureSEC source: 0000874015-26-000143 · edgardoc.xml · nonDerivative · entry 7 Monia Brett P · CIK 0001537529 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 260,253 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on December 8, 2025 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.005 to $76.00 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (5) on this Form 4. Read SEC document |
| March 10, 2026 Filed Mar 11, 2026 20:19 UTC |
Monia Brett PDirector · Chief Executive Officer
|
Exercise / conversionCommon Stock | 34,103 | $60.89 | $2,076,531.67 |
DisclosureSEC source: 0000874015-26-000143 · edgardoc.xml · nonDerivative · entry 6 Monia Brett P · CIK 0001537529 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 276,765 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 10, 2026 Filed Mar 11, 2026 20:18 UTC |
Jenne KyleEVP, Chf GL Pdt Str Ofcr
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 32,602 | $0.00 Strike: $46.10 | $0.00 |
DisclosureSEC source: 0000874015-26-000142 · edgardoc.xml · derivative · entry 6 Jenne Kyle · CIK 0001791857 · EVP, Chf GL Pdt Str Ofcr 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,601 Underlying: Common Stock · 32,602 shares Expires 2034-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 10, 2026 Filed Mar 11, 2026 20:18 UTC |
Jenne KyleEVP, Chf GL Pdt Str Ofcr
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 4,675 | $0.00 Strike: $34.69 | $0.00 |
DisclosureSEC source: 0000874015-26-000142 · edgardoc.xml · derivative · entry 5 Jenne Kyle · CIK 0001791857 · EVP, Chf GL Pdt Str Ofcr 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,025 Underlying: Common Stock · 4,675 shares Expires 2035-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 10, 2026 Filed Mar 11, 2026 20:18 UTC |
Jenne KyleEVP, Chf GL Pdt Str Ofcr
|
Exercise / conversionCommon Stock | 4,675 | $34.69 | $162,175.75 |
DisclosureSEC source: 0000874015-26-000142 · edgardoc.xml · nonDerivative · entry 4 Jenne Kyle · CIK 0001791857 · EVP, Chf GL Pdt Str Ofcr 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,389 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 10, 2026 Filed Mar 11, 2026 20:18 UTC |
Jenne KyleEVP, Chf GL Pdt Str Ofcr
|
SaleCommon Stock | 16,086 | $76.30 | $1,227,361.80 |
DisclosureSEC source: 0000874015-26-000142 · edgardoc.xml · nonDerivative · entry 3 Jenne Kyle · CIK 0001791857 · EVP, Chf GL Pdt Str Ofcr 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,714 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on December 8, 2025 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.02 to $76.60 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4. Read SEC document |
| March 10, 2026 Filed Mar 11, 2026 20:18 UTC |
Jenne KyleEVP, Chf GL Pdt Str Ofcr
|
SaleCommon Stock | 21,191 | $75.50 | $1,599,962.88 |
DisclosureSEC source: 0000874015-26-000142 · edgardoc.xml · nonDerivative · entry 2 Jenne Kyle · CIK 0001791857 · EVP, Chf GL Pdt Str Ofcr 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,800 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on December 8, 2025 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.005 to $76.00 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| March 10, 2026 Filed Mar 11, 2026 20:18 UTC |
Jenne KyleEVP, Chf GL Pdt Str Ofcr
|
Exercise / conversionCommon Stock | 32,602 | $46.10 | $1,502,952.20 |
DisclosureSEC source: 0000874015-26-000142 · edgardoc.xml · nonDerivative · entry 1 Jenne Kyle · CIK 0001791857 · EVP, Chf GL Pdt Str Ofcr 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 48,991 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 20:19 UTC |
O'NEIL PATRICK R.EVP CLO & General Counsel
|
SaleCommon Stock | 10,148 | $75.25 | $763,662.37 |
DisclosureSEC source: 0000874015-26-000144 · edgardoc.xml · nonDerivative · entry 1 O'NEIL PATRICK R. · CIK 0001564926 · EVP CLO & General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 62,211 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on December 8, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.98 to $75.51 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 20:19 UTC |
Monia Brett PDirector · Chief Executive Officer
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 73,529 | $0.00 Strike: $60.89 | $0.00 |
DisclosureSEC source: 0000874015-26-000143 · edgardoc.xml · derivative · entry 10 Monia Brett P · CIK 0001537529 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,103 Underlying: Common Stock · 73,529 shares Expires 2027-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 20:19 UTC |
Monia Brett PDirector · Chief Executive Officer
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 40,822 | $0.00 Strike: $60.89 | $0.00 |
DisclosureSEC source: 0000874015-26-000143 · edgardoc.xml · derivative · entry 9 Monia Brett P · CIK 0001537529 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 107,632 Underlying: Common Stock · 40,822 shares Expires 2027-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 20:19 UTC |
Monia Brett PDirector · Chief Executive Officer
|
SaleCommon Stock | 1,684 | $75.58 | $127,281.77 |
DisclosureSEC source: 0000874015-26-000143 · edgardoc.xml · nonDerivative · entry 5 Monia Brett P · CIK 0001537529 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 242,662 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on December 8, 2025 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.55 to $75.63 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) on this Form 4. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 20:19 UTC |
Monia Brett PDirector · Chief Executive Officer
|
SaleCommon Stock | 117,604 | $75.26 | $8,850,641.83 |
DisclosureSEC source: 0000874015-26-000143 · edgardoc.xml · nonDerivative · entry 4 Monia Brett P · CIK 0001537529 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 244,346 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on December 8, 2025 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.54 to $75.54 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 20:19 UTC |
Monia Brett PDirector · Chief Executive Officer
|
SaleCommon Stock | 7,382 | $74.11 | $547,087.40 |
DisclosureSEC source: 0000874015-26-000143 · edgardoc.xml · nonDerivative · entry 3 Monia Brett P · CIK 0001537529 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 361,950 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on December 8, 2025 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.44 to $74.42 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 20:19 UTC |
Monia Brett PDirector · Chief Executive Officer
|
Exercise / conversionCommon Stock | 73,529 | $60.89 | $4,477,180.81 |
DisclosureSEC source: 0000874015-26-000143 · edgardoc.xml · nonDerivative · entry 2 Monia Brett P · CIK 0001537529 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 369,332 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 20:19 UTC |
Monia Brett PDirector · Chief Executive Officer
|
Exercise / conversionCommon Stock | 40,822 | $60.89 | $2,485,651.58 |
DisclosureSEC source: 0000874015-26-000143 · edgardoc.xml · nonDerivative · entry 1 Monia Brett P · CIK 0001537529 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 295,803 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 04, 2026 Filed Mar 5, 2026 23:14 UTC |
LOSCALZO JOSEPHDirector
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 200 | $0.00 Strike: $38.06 | $0.00 |
DisclosureSEC source: 0000874015-26-000138 · edgardoc.xml · derivative · entry 6 LOSCALZO JOSEPH · CIK 0001276128 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,968 Underlying: Common Stock · 200 shares Expires 2032-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 04, 2026 Filed Mar 5, 2026 23:14 UTC |
LOSCALZO JOSEPHDirector
|
SaleCommon Stock | 200 | $80.00 | $16,000.00 |
DisclosureSEC source: 0000874015-26-000138 · edgardoc.xml · nonDerivative · entry 4 LOSCALZO JOSEPH · CIK 0001276128 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,330 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 18, 2025. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.